These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

82 related articles for article (PubMed ID: 2692134)

  • 1. [Joint tolerance of pefloxacin and ofloxacin in children and adolescents with cystic fibrosis].
    Pertuiset E; Lenoir G; Jehanne M; Douchain F; Guillot M; Menkès CJ
    Rev Rhum Mal Osteoartic; 1989 Nov; 56(11):735-40. PubMed ID: 2692134
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [Arthropathies following the administration of pefloxacin to an adolescent with mucoviscidosis].
    Kesseler A; Lacassie A; Hugot JP; Talon P; Thomas D; Astier L
    Ann Pediatr (Paris); 1989 Apr; 36(4):275-8. PubMed ID: 2742312
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [Comparative efficacy and safety of ciprofloxacin, ofloxacin, and pefloxacin in treatment of respiratory infections in children with cystic fibrosis].
    Postnikov SS
    Antibiot Khimioter; 2001; 46(3):16-20. PubMed ID: 11548276
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Use of quinolones in the treatment of Pseudomonas aeruginosa infections in children with cystic fibrosis].
    Milio MC; Campana S
    Pediatr Med Chir; 1995; 17(1):53-5. PubMed ID: 7739928
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Pefloxacin in the treatment of recurrent urinary tract infections].
    Oksa A; Dzúriková V; Gajdos M; Krechnáková A; Krivosíková G; Ploczeková C; Spustová V
    Cas Lek Cesk; 1990 Jul; 129(30):953-6. PubMed ID: 2208227
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Critical risk/benefit analysis of pefloxacine use in children under 15 years--the problem of arthralgias.
    Chevais M; Reinert P; Rondeau MC; Tobelem R; Albengres E; Riant P; Tillement JP
    Int J Clin Pharmacol Ther Toxicol; 1987 Jun; 25(6):306-9. PubMed ID: 3476471
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Pefloxacin in the treatment of patients with mucoviscidosis].
    Postnikov SS; Semykin SIu; Polikarpova SV; Nazhimov VP
    Antibiot Khimioter; 2002; 47(4):13-5. PubMed ID: 12369138
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Exacerbation of myasthenia gravis by pefloxacin].
    Vial T; Chauplannaz G; Brunel P; Leriche B; Evreux JC
    Rev Neurol (Paris); 1995 Apr; 151(4):286-7. PubMed ID: 7481384
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [On fluoroquinolones treatment safety in children (clinical, morphological and catamnesis data)].
    Postnikov SS; Semykin SIu; Nazhimov VP; Novichkova GA
    Antibiot Khimioter; 2002; 47(9):14-7. PubMed ID: 12619515
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Fluoroquinolones in children: poorly defined risk of joint damage.
    Prescrire Int; 2004 Oct; 13(73):184-6. PubMed ID: 15499700
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Retrospective survey of fluoroquinolone use in children].
    Pariente-Khayat A; Vauzelle-Kervroedan F; d'Athis P; Bréart G; Gendrel D; Aujard Y; Olive G; Pons G
    Arch Pediatr; 1998 May; 5(5):484-8. PubMed ID: 9759180
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Concentrations of the des-F(6)-quinolone garenoxacin in plasma and joint cartilage of immature rats.
    Kastner M; Rahm U; Baumann-Wilschke I; Bello A; Stahlmann R
    Arch Toxicol; 2004 Feb; 78(2):61-7. PubMed ID: 14661070
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Degeneration of normal articular cartilage induced by late phase osteoarthritic synovial fluid in beagle dogs.
    Xu QR; Dong YH; Chen SL; Bao CD; Du H
    Tissue Cell; 2009 Feb; 41(1):13-22. PubMed ID: 18692211
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [A new quinolone (pefloxacine) in bronchopulmonary superinfections in cystic fibrosis].
    Reineri P; Squinazi F; Tobelem R; Lemerle S; Lobut JB; Bernaudin F; Kohout G; Bouveret
    Pediatrie; 1984; 39(7):597-8. PubMed ID: 6598489
    [No Abstract]   [Full Text] [Related]  

  • 15. Early pathophysiologic feature of arthropathy in juvenile dogs induced by ofloxacin, a quinolone antimicrobial agent.
    Yabe K; Satoh H; Ishii Y; Jindo T; Sugawara T; Furuhama K; Goryo M; Okada K
    Vet Pathol; 2004 Nov; 41(6):673-81. PubMed ID: 15557076
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Photoonycholysis induced by the fluoroquinolones pefloxacine and ofloxacine. Report on 2 cases.
    Baran R; Brun P
    Dermatologica; 1986; 173(4):185-8. PubMed ID: 2945743
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Magnetic resonance imaging in children receiving quinolones: no evidence of quinolone-induced arthropathy. A multicenter survey.
    Danisovicová A; Brezina M; Belan S; Kayserová H; Kaiserová E; Hruskovic I; Orosová K; Dluholucký S; Galova K; Mathéova E
    Chemotherapy; 1994; 40(3):209-14. PubMed ID: 8205939
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Use of high-dose ibuprofen in a pediatric cystic fibrosis center.
    Fennell PB; Quante J; Wilson K; Boyle M; Strunk R; Ferkol T
    J Cyst Fibros; 2007 Apr; 6(2):153-8. PubMed ID: 16844429
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [An attempt to use ofloxacin in patients with mucoviscidosis].
    Chuchalin AG; Sokolov AS; Apul'tsina ID; GUgutsidze EN; Kuchkina NV; Samsonova MV
    Antibiot Khimioter; 1996; 41(9):43-6. PubMed ID: 9005785
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Pancreatitis among patients with cystic fibrosis: correlation with pancreatic status and genotype.
    De Boeck K; Weren M; Proesmans M; Kerem E
    Pediatrics; 2005 Apr; 115(4):e463-9. PubMed ID: 15772171
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.